NASDAQ: GNLXGenelux Corp Stock Ownership - Who owns Genelux?
Insider buying vs selling
Have Genelux Corp insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Thomas Zindrick | CEO;Pres | 2026-08-31 | 34,463 | $2.67 | $91.91kSell |
| Joseph Cappello | CTO | 2026-08-31 | 10,257 | $2.74 | $28.11kSell |
| Yong Yu | CSci | 2026-08-31 | 9,683 | $2.75 | $26.66kSell |
| Joseph Cappello | CTO | 2026-08-04 | 653 | $2.95 | $1.92kSell |
| Yong Yu | CSci | 2026-08-04 | 653 | $2.94 | $1.92kSell |
| Thomas Zindrick | CEO;Pres | 2026-08-04 | 3,023 | $2.95 | $8.91kSell |
| John W. Smither | Director | 2026-07-01 | 12,000 | $2.91 | $34.90kSell |
| Ralph Smalling | Head of Regulatory | 2026-06-03 | 192 | $2.93 | $562.56Sell |
| John Thomas | Director | 2026-06-01 | 10,000 | $2.98 | $29.80kSell |
| Ralph Smalling | Head of Regulatory | 2026-05-11 | 270 | $2.98 | $804.60Sell |
GNLX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GNLX insiders and whales buy or sell their stock.
GNLX Shareholders
What type of owners hold Genelux Corp stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Thomas Zindrick | 3.15% | 1,426,427 | $3.61M | Insider |
| Aladar Szalay | 1.23% | 555,000 | $1.40M | Insider |
| John Thomas | 1.11% | 501,193 | $1.27M | Insider |
| Joseph Cappello | 0.70% | 318,480 | $805.75k | Insider |
| Matthew Pulisic | 0.62% | 278,906 | $705.63k | Insider |
| Yong Yu | 0.57% | 258,688 | $654.48k | Insider |
| Eric Groen | 0.52% | 233,957 | $591.91k | Insider |
| Tony Yu | 0.35% | 159,000 | $402.27k | Insider |
| Qian Zhang | 0.31% | 139,533 | $353.02k | Insider |
| Mary Mirabelli | 0.23% | 102,693 | $259.81k | Insider |
GNLX vs Biotech Stocks
Genelux Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.